Dr Raez speaks with ecancertv at the Best of ASCO 2016 about developments in immunotherapy to treat lung cancer.

He describes the improved patient outcomes resulting from combined immunotherapy treatment, and how to cope with associated toxicities.

Dr Raez also highlights the potential of CAR-T cell therapy to treat lung cancer.

Combined courses of ipilimumab and nivolumab have been approved in the UK to treat melanoma, and it was recently reported that PD-L1 selection improved cost effectiveness of nivolumab as a single agent against NSCLC.